WallStSmart

Azitra Inc (AZTR)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZTR leads profitability with a 0.0% profit margin vs -141.4%. AZTR earns a higher WallStSmart Score of 24/100 (F).

AZTR

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 6.7Quality: 6.0
Piotroski: 1/9Altman Z: -23.94

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AZTR.

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZTR3 strengths · Avg: 10.0/10
P/E RatioValuation
8.9x10/10

Attractively priced relative to earnings

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

AZTR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.79M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AZTR

The strongest argument for AZTR centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : AZTR

The primary concerns for AZTR are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

AZTR profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

MRNA carries more volatility with a beta of 1.11 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

AZTR generates stronger free cash flow (-3M), providing more financial flexibility.

Bottom Line

AZTR scores higher overall (24/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Azitra Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Azitra Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. The company is headquartered in Branford, Connecticut.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?